together: “Инстинкт самосохранения” plus 49 more |  |
- Инстинкт самосохранения
- Image
- academic2
- Что у них в голове
- Don't have Telegram yet? Try it now!
- JFrog To Participate At Upcoming Investor Conferences
- AMD Could Shift To Samsung From TSMC For 3nm Chips
- Секс в кино
- Уничтожение женского спорта
- Clearmind Medicine Launches Study For Binge Eating With The Hebrew University Using Its Proprietary MEAI Compound
- Flow Beverage Corp. Announces Executive Leadership Changes And Ongoing Organizational Streamlining
- academic2
- Global Health Insurance Market Report 2021: Focus On Health Maintenance Organization (HMO) Plans, Preferred Provider Organization (PPO) Plans, & Exclusive Provider Organization (EPO) Plans
- Supernus Pharmaceuticals Completes Acquisition Of Adamas Pharmaceuticals
- Image
- academic2
- Daily Digest: If New feed item from http://feed.informer.com/digests/AOOUJ41VE9/feeder.rss, then Add
- Сборы утром и утренняя рутина
- Daily Digest: If New feed item from http://feed.informer.com/digests/AOOUJ41VE9/feeder.rss, then Add
- Причаль
- Как всё было на самом деле
- Начальника полиции Долгопрудного задержали за переправку в США граждан Индии
- Enacademic
- Арктика пошла на рекорд холода. Вулканическая зима все ближе
- Причаль
- academic2
- Граф Котовский
- Image together (RSS)
- Что у них в голове
- 5 Black Friday Shopping Tips for New Homeowners
- Comment your favourite anime please I have nothing to watch
- Telegram Widget
- Видео для товаров полиция - Форма одежды
- DBV Technologies To Participate In An Upcoming Investor Conference
- IIROC Trading Resumption - MCLD
- These Are the Unexpected Christmas Decor Trends in 2021, According to Experts
- Cursed doctor
- OnePlus Plans To Announce A Foldable Smartphone, But Not Anytime Soon
- Mozilla прекращает поддержку менеджера паролей Firefox Lockwise
- Уничтожение женского спорта
- Mastercard Expands Support Of Latin America Real-Time Payments With Acquisition Of Arcus
- Аллергия на холод: что это такое и как с ней бороться
- Лёгким движением руки...
- Daily Digest: If New feed item from https://clck.ru/P5rK2, then Add to daily digest sent to analogin
- Путин, что ты делаешь, прекрати
- Enacademic
- Don't have Telegram yet
- This TikTok-Famous Planner Has Helped Make My Busy Days Way More Manageable — and It’s on Sale!
- PAOG Acquisition To Expand CBD IP Portfolio Scheduled To Close December 3rd
- Don't have Telegram yet? Try it now!
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Posted: 23 Nov 2021 11:14 PM PST  | ||
| Posted: 24 Nov 2021 03:06 AM PST academic2academic2.ru This posting includes an audio/video/photo media file: Download Now | ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Don't have Telegram yet? Try it now! Posted: 24 Nov 2021 04:31 AM PST | ||
| JFrog To Participate At Upcoming Investor Conferences Posted: 24 Nov 2021 06:15 AM PST JFrog Ltd. ("JFrog") (FROG) , the Liquid Software company and creators of the JFrog DevOps Platform, today announced its participation in the following upcoming investor conferences:
Live webcasts, as well as replays, will be available on the Company's investor relations website at https://investors.jfrog.com/events-and-presentations/events. About JFrog JFrog is on a mission to be the company powering all of the world's software updates, driven by a "Liquid Software" vision to allow the seamless, secure flow of binaries from developers to the edge. The company's end-to-end DevOps platform - the JFrog Platform - provides the tools and visibility required by modern organizations to solve today's challenges across critical pieces of the DevOps cycle. JFrog's hybrid, universal, multi-cloud DevOps platform is available as both self-managed and SaaS services on AWS, Microsoft Azure, and Google Cloud. JFrog is trusted by millions of users and thousands of customers, including a majority of the Fortune 100 companies that depend on JFrog solutions to manage their mission-critical software delivery pipelines. Learn more at jfrog.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005824/en/ | ||
| AMD Could Shift To Samsung From TSMC For 3nm Chips Posted: 24 Nov 2021 05:01 AM PST | ||
| Posted: 24 Nov 2021 03:51 AM PST  Секс в кино. Обсуждаем в подкасте «Смотритель» together (RSS) Про съёмки эротических эпизодов в эпоху пандемии, откровенные сцены в советских фильмах и порнопародии. | ||
| Posted: 24 Nov 2021 05:40 AM PST Уничтожение женского спорта https://ift.tt/3DQ8EZN | ||
| Posted: 24 Nov 2021 06:18 AM PST F ocus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (" Clearmind" or the " Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has signed an agreement to fund a new research and development project with the Hebrew University of Jerusalem's Obesity and Metabolism Laboratory, to evaluate the Company's proprietary compound, MEAI's direct effect on binge eating including food and water intakes as well as activity and metabolic parameters. The study, which will be overseen by Prof. Joseph (Yossi) Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University's Institute for Drug Research, will focus on testing the potential of MEAI to treat binge eating and related behaviors, and will support the discovery and development of novel therapeutic strategies to safely treat obesity and its associated metabolic disorders. Increasingly prevalent in developed nations, the conditions of being overweight and obese are a serious health concern as they contribute to so many other conditions, including heart disease, stroke, type 2 diabetes, fatty liver disease, and certain types of cancers, some of the leading causes of preventable, premature death in the US. The Center for Disease Control and Prevention estimates that about 74% of adults in the US are overweight 1 and over 40% are considered obese 2 . According to a recent study published in 2020, this phenomenon is also accompanied with the high and rising costs of obesity to the US Health Care system at an estimated annual medical cost for the full non-institutionalized population of adults, in 2013, equaling $342.2 billion 3 . Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, "The medical community has yet to establish an effective therapeutic or preventative treatment for obesity, despite its increasing prevalence and severe negative impacts on the medical and economic health of people around the world. Clearmind has been able to demonstrate the positive influence MEAI has on binge behavior with regard to alcohol use, and our preliminary research indicates it may have a similar effect on metabolic disorders." Prof. Tam added, "I have spent my career exploring the biological mechanisms underlying obesity and the metabolic syndrome, intending to develop an effective drug therapy. After viewing the early data on MEAI, I am optimistic that this compound has the potential to be a building block for a real solution and look forward to working with the Clearmind team to advance our shared objective." The first phase of the three-stage study will focus on assessing the direct effect of MEAI on food and water intakes as well as its ability to modulate activity and metabolic parameters. Following the initial screening, the study will evaluate MEAI's efficacy as a therapeutic metabolic agent on a high-fat diet-induced obese mouse model, by measuring MEAI's potential to treat obesity, hepatic injury, glycemic and hormonal imbalance. Lastly MEAI's binge eating and drinking mitigating properties will be determined by comparison of cumulative food and sucrose preference, respectively. About Clearmind Medicine Inc. Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of four patent families. The first, "Binge Behavior Regulators", has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, "Alcohol Beverage Substitute", has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol " CMND", the Frankfurt Stock Exchange under the symbol " CWYO" and on the OTC Pink under the symbol " CMNDF". For further information, please contact:Investor Relations,Email: invest@clearmindmedicine.comTelephone: (778) 400-5347General Inquiries, Info@Clearmindmedicine.com www.Clearmindmedicine.com FORWARD-LOOKING STATEMENTS: This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include discussion of the new research and development project with the Hebrew University of Jerusalem's Obesity and Metabolism Laboratory and the benefits of product candidate. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither the Canadian Securities Exchange (the " CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. | ||
| Flow Beverage Corp. Announces Executive Leadership Changes And Ongoing Organizational Streamlining Posted: 24 Nov 2021 06:20 AM PST Flow Beverage Corp. (TSX:FLOW)(OTCQX:FLWBF) ("Flow" or the "Company"), today announced changes to its executive leadership team. President and Chief Operating Officer, David Mock, will be departing the Company, and Kevin Helfand will be promoted to Chief Legal and Human Resources Officer. "Flow continues to implement a more streamlined and simplified structure to execute on its profitable growth plans. This reorganization will empower decision making, reduce management layers, streamline communication and allow Flow to better execute its 2022 strategic framework. We would like to thank David Mock for his leadership and strong commitment to Flow. He has significantly contributed to establishing Flow as an admired brand across Canada and the United States. We wish him all success in the continuation of his distinguished career," said Maurizio Patarnello, Chief Executive Officer of Flow. Flow's executive leadership team will consist of Chief Executive Officer, Maurizio Patarnello; Chief Financial Officer, Devan Pennell; Chief Marketing Officer, Krissie Millan; Chief Revenue Officer, Tim Dwyer; and Chief Legal and Human Resources Officer, Kevin Helfand. Adrian Ross has also been newly appointed to the role of Senior Vice President of Operations. Mr. Ross has extensive international experience in both plant operations and the delivery of technical service solutions with companies including Tetra Pak Group and Campbell Soup Company. Mr. Ross will be reporting to Flow's Chief Executive Officer. ABOUT FLOW Flow is a premium alkaline spring water company with a diversified line of health and wellness-oriented beverage products sold online and at retailers throughout North America. Flow's premium alkaline spring water is offered in original unflavored and a range of award-winning organic flavors, in sizes ranging from 330-ml to 1-liter. Due to its unique artesian spring sources, Flow products contain naturally occurring electrolytes and essential minerals, and its original and flavored water products have an alkaline pH. As part of its ongoing innovation into functional "better-for-you" beverages, Flow recently introduced a new line of collagen-infused waters with natural flavors. Founded in 2014 by serial, mission-driven entrepreneur Nicholas Reichenbach, Flow is highly dedicated to sustainability and is a B-Corp Certified company with a purpose to "bring wellness to the world through the positive power of water." Flow set out to be a sustainable brand, packaging its products in up to 75% renewable-resource-based Tetra Pak™ cartons utilizing sustainable operations. Flow beverage products are available online at flowhydration.com, and are sold at over 20,000 stores across the United States and Canada, including Target, Publix, Walmart, Costco, Whole Foods Market, Loblaws, Sobeys, Metro, Shoppers Drug Mart, Farm Boy, Sprouts Farmers Market, Safeway, Wegmans, Harris Teeter, Giant Eagle, Bristol Farms, Raley's, and Duane Reade, among others. Follow Flow on social media: Instagram ( https://www.instagram.com/flow/); Twitter ( https://twitter.com/FlowHydration); and Facebook ( facebook.com/FlowHydration). For more information on Flow, please visit Flow's investor relations site at: investors.flowhydration.com Cautionary Statement This press release may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Such forward-looking statements include, but are not limited to, information with respect to our objectives and the strategies for achieving those objectives, as well as information with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. Forward-looking statements are typically identified by the use of words such as "may", "would", "should", "could", "expect", "intend", "estimate", "anticipate", "plan", "foresee", "believe", or "continue", although not all forward-looking statements contain these words. Forward-looking statements are provided for the purposes of assisting the reader in understanding Flow and its business, operations, prospects, and risks at a point in time in the context of historical and possible future developments, and the reader is therefore cautioned that such information may not be appropriate for other purposes. Forward-looking statements are based on assumptions and are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking statements. Those risks and uncertainties include the following: impact and spread of COVID-19; ability to achieve and manage growth; failure to expand sales capabilities; changes in consumer preferences; criticism of packaged water; maintain brand image and product quality; constrained or unavailable spring water sources; inability to package products; increased competition; accurately estimating demand; maintaining relationships with distributors and vendors; changing retail landscape; incorrect product design or development; product information misrepresentation; revenues derived entirely from packaged beverages; increases in costs or shortages of materials; fluctuation of quarterly operating results; no assurance of profitability; fluctuations in foreign currency; changes in government regulation; contamination or recalls of ingredients or end products; loss of intellectual property rights; litigation; future tax rates; catastrophic events; climate change; seasonal business; dependence on key information systems and third-party service providers; ability to securely maintain confidential information; maintaining and upgrading information technology systems; conflict of interest; dual class share structure; potential volatility of share price; no assurance of active market for shares; lack of dividends; global financial condition; publication of inaccurate or unfavourable research and reports; operating history; and management and conflict of interests. Consequently, all of the forward-looking statements contained herein are qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the expected consequences or effects on our business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking statements contained herein are provided as of the date hereof, and we do not undertake to update or amend such forward-looking statements whether as a result of new information, future events or otherwise, except as may be required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124006036/en/ | ||
| Posted: 24 Nov 2021 03:06 AM PST academic2academic2.ru | ||
| Posted: 24 Nov 2021 06:15 AM PST DUBLIN, Nov. 24, 2021 /PRNewswire/ -- The "Health Insurance Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The global health Insurance market is evaluated at US$79.254 billion for the year 2019 and is projected to grow at a CAGR of 4.71% to reach US$109.383 billion in 2026.Health Insurance is an insurance solution that provides for the medical and surgical expenses of a person who has taken this policy. It functions in two ways either it provides reimbursement of the expenditure incurred due to illness or injury or it pays a specific amount directly to the care provider. The increase in medical costs or medical care expenses globally is driving the market for health insurance. Moreover, the rapid growth of chronic diseases among the population across the globe such as heart disease, cancer, type 2 diabetes, and arthritis, and the rise in the aging population has further contributed to the expansion of the market. However, the cost associated with health insurance may act as a market constraint. Increase in healthcare expenditure to drive the growth of the market.The increase in healthcare expenses is the prime driver of the market. Healthcare insurance acts as a risk mitigation measure for consumers globally. The increase in health expenditure both by the individuals and governments is rising. According to the report on global health expenditure released by the World Health Organization (WHO) on February 20, 2019, global expenditure on health increased in low and middle-income countries by 6 percent and in high-income countries by 4 percent. The Indian Government, as per the Ministry of Finance is looking to increase public spending on healthcare services from 1 percent to 2.5-3 percent of GDP, as envisaged in the National Health Policy of the country. The US Center for Medicare and Medicaid Services in its report estimated that national health care spending reached $3.81 trillion in 2019 and increased to $4.01 trillion in 2020. CMS projected that by 2028, health care spending would reach $6.19 trillion, and would account for 19.7% of GDP, up from 17.7% in 2018 in the US. The increasing healthcare expenditures point to the opportunity in the health insurance market. Expanding penetration of chronic diseases to raise the market demand.The expanding penetration of chronic diseases among the population across the globe such as heart disease, cancer, type 2 diabetes, and arthritis, and the rise in the aging population has further contributed to the growth of the market. As reported by US National Center for Biotechnology Information, one in every three adults lives with more than one chronic condition, or multiple chronic conditions and procure an excessive health and cost burden. The mentioned figure is near to three out of four in older adults residing in developed economies and is estimated to incline drastically with the proportion of patients with more than four diseases almost doubling between 2015 and 2035 in the UK. Rising awareness regarding health insurance benefits to facilitate market expansion.The rising awareness about the benefits of health insurance is predicted to further expand the market size of the health insurance market. Moreover, the awareness among the people living in rural areas is also increasing. As per the United States Center for Medicare and Medicaid Services, Private health insurance spending grew 3.7% to $1,195.1 billion in 2019 amounting to 31 percent of total National Healthcare Expenditure. Especially owing to the advent of the COVID-19 pandemic outbreak.In June 2021, Exela Technologies, Inc., a global business process automation company, announced the extension and expansion of its partnership with specialty care services insurance carriers, PCH Global. This engagement leverages Exela's powerful cloud-based digital exchange platform for PCH Global to expand the current deployment to approximately 3,800 specialists as registered users within the customer organization using Exela's proprietary workflow and rule engines across all aspects of the health claims spectrum including behavioral health.In June 2021, Now Health International Group, an International Private Medical Insurance provider, announced a new program with Starr Insurance Companies, a global insurance company, to take ahead its growth plans in Europe. This program incorporates Now Health International's global presence and expertise in providing high-quality international health insurance solutions and digital tools, with Starr's long-standing global knowledge and capability to deliver customized solutions across Europe. High cost and longer time for claim reimbursement to restrain the market growth.However, the high cost associated with health insurance, lack of knowledge about coverages included in the health insurance policy, strict regulations, and longer time for claim reimbursement may constraint the growth of the health insurance market.Geographically, North America will dominate the market holding the largest share in the forecast period owing to the availability of multi-value health insurance policies, provision of favorable health insurance landscape in the U.S, and presence of key market players in the region. Moreover, escalating disposable income, improvement of health standard system, and increasing healthcare expenditure are estimated to positively impact the health insurance market in the Asia Pacific. Company Profiles
Market Segmentation: By Type
By Service Provider
By Geography
For more information about this report visit https://www.researchandmarkets.com/r/tguhko Media Contact: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets | ||
| Supernus Pharmaceuticals Completes Acquisition Of Adamas Pharmaceuticals Posted: 24 Nov 2021 06:12 AM PST ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). "Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "In addition, the acquisition adds a new growth catalyst, diversifies our revenue base and cash flow, and is expected to be significantly accretive in 2022." Compelling Strategic Rationale
The Offer and the Merger The tender offer (Offer) for all outstanding shares of common stock of Adamas for (1) $8.10 per Share, in cash, less any applicable withholding taxes and without interest (Cash Amount), plus (2) two non-transferable and non-tradable contingent value rights per Share, each of which represents the contractual right to receive a contingent payments of $0.50 in cash, less any applicable withholding taxes and without interest (each, a CVR), which amount will become payable, if at all, if specified milestones are achieved prior to December 31, 2024 and December 31, 2025, as applicable (collectively, the Cash Amount with the CVRs, the Offer Price), expired as scheduled at one minute following 11:59 p.m., New York time, on November 23, 2021. American Stock Transfer & Trust Company, LLC, the depositary for the Offer, has advised Supernus that a total of 35,478,225 Adamas shares were validly tendered and not properly withdrawn in the Offer, representing approximately 77.3 percent of the shares of Adamas common stock outstanding. All of the conditions of the Offer have been satisfied, and on November 24, 2021, Supernus and its wholly-owned subsidiary, Supernus Reef, Inc. (Reef), accepted for payment all Adamas shares that were validly tendered and not properly withdrawn in the Offer, and will as promptly as practical pay for all such validly tendered shares. Following the completion of the Offer, Supernus completed the acquisition of Adamas through the merger of Reef with and into Adamas, without a vote of Adamas stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (DGCL), with Adamas surviving the merger as a wholly-owned subsidiary of Supernus. In connection with the merger, each Adamas share not previously purchased in the Offer (other than (i) Adamas shares held by Adamas (or held in Adamas' treasury) immediately prior to the effective time of the merger, (ii) any Adamas shares held by Supernus or any direct or indirect wholly owned subsidiary of Supernus immediately prior to the effective time of the merger, or (iii) Adamas shares held by any stockholder who was entitled to demand and properly demanded appraisal of such shares pursuant to, and who complied in all respects with, Section 262 of the DGCL and who, as of the effective time of the merger, has neither effectively withdrawn nor lost its rights to such appraisal and payment under the DGCL with respect to such shares) was converted into the right to receive the Offer Price, less any applicable withholding taxes and without interest. Adamas's common stock will be delisted from the NASDAQ Stock Market. Each CVR paid to Adamas stockholders represents a non-transferable and non-tradable contractual contingent right to receive a cash payment of $0.50, without interest and less any required withholding taxes, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into among Supernus and American Stock Transfer & Trust Company, LLC, as rights agent, (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI® in excess of $150,000,000 during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225,000,000 during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once. The maximum amount payable with respect to the two CVRs issued in respect to each Share is $1.00 in the aggregate. There can be no assurance any payments will be made with respect to any CVR. Advisors Jefferies LLC acted as the exclusive financial advisor to Supernus. Lazard acted as the exclusive financial advisor to Adamas. Saul Ewing Arnstein & Lehr LLP served as legal counsel and Grant Thornton provided due diligence services to Supernus, and Cooley LLP served as legal counsel to Adamas. About Supernus Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson's disease, epilepsy, depression and rare CNS disorders. For more information, visit www.supernus.com Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the risk that the effects of disruption from the transactions of Adamas's business and the fact that the transactions may make it more difficult to establish or maintain relationships with employees, manufactures, suppliers, vendors, business partners and distribution channels to patients; the risk that stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification and liability; the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products and products acquired through the acquisition of Adamas; the Company's ability to increase its net revenue from its products and products acquired through the acquisition of Adamas; the Company's ability to commercialize its products including Qelbree; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events. Supernus ContactsJack A. Khattar, President and CEOTimothy C. Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301) 838-2591 or Investors:Peter VozzoICR WestwickeOffice: (443) 213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com | ||
| Posted: 24 Nov 2021 03:06 AM PST  | ||
| Posted: 24 Nov 2021 03:06 AM PST academic2academic2.ru | ||
| Daily Digest: If New feed item from http://feed.informer.com/digests/AOOUJ41VE9/feeder.rss, then Add Posted: 23 Nov 2021 08:17 PM PST ----- [28 items] ----- ============================ Такие дела together (RSS) Такие дела - (added at November 12, 2021 at 08:11AM) https://ift.tt/3qDLnGq Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qDLnGq ============================ academic2 - (added at November 12, 2021 at 09:11AM) https://ift.tt/3wAhDvn Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3wAhDvn ============================ academic2 - (added at November 12, 2021 at 12:10PM) https://ift.tt/3wBXHbv Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3wBXHbv ============================ Такие дела together (RSS) Такие дела - (added at November 12, 2021 at 01:10PM) https://ift.tt/3qDLnGq Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qDLnGq ============================ Image - (added at November 12, 2021 at 03:11PM) https://ift.tt/30mSV5S Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/30mSV5S ============================ Image - (added at November 12, 2021 at 03:11PM) https://ift.tt/3n5zJlA Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3n5zJlA ============================ academic2 - (added at November 12, 2021 at 03:11PM) https://ift.tt/3C9sYn2 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3C9sYn2 ============================ academic2 - (added at November 12, 2021 at 04:10PM) https://ift.tt/3EZu5HY Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3EZu5HY ============================ Social posts Download Link || - (added at November 12, 2021 at 05:11PM) https://ift.tt/3c4pCHn Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3c4pCHn ============================ How to Turn Off and Wake Every Single Apple Watch together (RSS) - (added at November 12, 2021 at 07:14PM) https://ift.tt/3kvVcmi Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3kvVcmi ============================ academic2 - (added at November 12, 2021 at 08:11PM) https://ift.tt/3C9sYn2 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3C9sYn2 ============================ academic2 - (added at November 12, 2021 at 08:11PM) https://ift.tt/3wAhDvn Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3wAhDvn ============================ Image - (added at November 12, 2021 at 09:10PM) https://ift.tt/3DbPNI2 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3DbPNI2 ============================ Image - (added at November 12, 2021 at 09:10PM) https://ift.tt/3oqqE6k Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3oqqE6k ============================ academic2 - (added at November 12, 2021 at 10:10PM) https://ift.tt/3EZu5HY Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3EZu5HY ============================ Такие дела together (RSS) Такие дела - (added at November 12, 2021 at 10:10PM) https://ift.tt/3qDLnGq Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qDLnGq ============================ academic2 - (added at November 12, 2021 at 10:10PM) https://ift.tt/3wFbWw5 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3wFbWw5 ============================ Image - (added at November 13, 2021 at 01:10AM) https://ift.tt/3n9I3Ry Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3n9I3Ry ============================ academic2 - (added at November 13, 2021 at 01:10AM) https://ift.tt/3opAIwv Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3opAIwv ============================ Image - (added at November 13, 2021 at 01:10AM) https://ift.tt/3n5zJlA Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3n5zJlA ============================ academic2 - (added at November 13, 2021 at 01:10AM) https://ift.tt/3HjSSZ6 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3HjSSZ6 ============================ Don't have Telegram yet? - (added at November 13, 2021 at 02:15AM) https://ift.tt/3qMAwKL Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qMAwKL ============================ Такие дела together (RSS) Такие дела - (added at November 13, 2021 at 03:18AM) https://ift.tt/3qDLnGq Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qDLnGq ============================ academic2 - (added at November 13, 2021 at 03:18AM) https://ift.tt/3kzMkfo Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3kzMkfo ============================ How to Turn Off and Wake Every Single Apple Watch together (RSS) - (added at November 13, 2021 at 03:18AM) https://ift.tt/3kvVcmi Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3kvVcmi ============================ academic2 - (added at November 13, 2021 at 04:21AM) https://ift.tt/3C9sYn2 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3C9sYn2 ============================ Image - (added at November 13, 2021 at 04:21AM) https://ift.tt/3CgrzuV Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3CgrzuV ============================ Image - (added at November 13, 2021 at 05:14AM) https://ift.tt/3Dek1dz Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3Dek1dz IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580794 | ||
| Posted: 24 Nov 2021 05:00 AM PST | ||
| Daily Digest: If New feed item from http://feed.informer.com/digests/AOOUJ41VE9/feeder.rss, then Add Posted: 23 Nov 2021 08:17 PM PST ----- [34 items] ----- ============================ https://ift.tt/3nzkUba - (added at November 21, 2021 at 08:10AM) https://ift.tt/3Fqb5CG Enacademic via full digest https://ift.tt/3Fqb5CG ============================ https://ift.tt/3CGQhVv - (added at November 21, 2021 at 08:10AM) https://ift.tt/2ZbqcAu Vision Bot in Enacademic Enacademic via full digest https://t.me/enacademicgroup/6675927?embed=1 ============================ academic2 - (added at November 21, 2021 at 08:10AM) https://ift.tt/3oQo9KX Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3oQo9KX ============================ Image - (added at November 21, 2021 at 09:10AM) https://ift.tt/3Cywrf5 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3Cywrf5 ============================ academic2 - (added at November 21, 2021 at 10:10AM) https://ift.tt/3nDZSYU Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3nDZSYU ============================ academic2 - (added at November 21, 2021 at 10:10AM) https://ift.tt/3x4xLoU Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3x4xLoU ============================ academic2 - (added at November 21, 2021 at 12:10PM) https://ift.tt/3oQo9KX Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3oQo9KX ============================ academic2 - (added at November 21, 2021 at 01:10PM) https://ift.tt/30E4GEO Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/30E4GEO ============================ https://ift.tt/3CGQhVv - (added at November 21, 2021 at 02:10PM) https://ift.tt/2ZbqcAu Vision Bot in Enacademic Enacademic via full digest https://t.me/enacademicgroup/6675927?embed=1 ============================ store.academic2.ru - urlscan.io - (added at November 21, 2021 at 02:10PM) https://ift.tt/33j2Ffv Not observed on urlscan.io Live Screenshot Hover to expand No direct hits Nothing is hosted on this domain No incoming hits Nothing talked to this domain DNS recordsRetrieved via DNS ANY query A 138.201.81.43 (TTL: 300) TXT yandex-verification: 11664def4b78652f TXT wmail-verification: 6bc98baf4df82d6f3e56069a4d8488ee WHOIS for store.academic2.ru domain: ACADEMIC2.RU nserver: flamingo.ezoicns.com. nserver: lionfish.ezoicns.com. nserver: starfish.ezoicns.com. state: REGISTERED, DELEGATED, VERIFIED person: Private Person registrar: RU-CENTER-RU admin-contact: https://www.nic.ru/whois created: 2019-08-09T01:22:10Z paid-till: 2022-08-09T01:22:10Z free-date: 2022-09-09 source: TCI Last updated on 2021-11-20T01:46:31Z Adblock test (Why?) via full digest https://ift.tt/33j2Ffv ============================ Image - (added at November 21, 2021 at 03:10PM) https://ift.tt/3CxXIyl Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3CxXIyl ============================ Store.academic2.ru - (added at November 21, 2021 at 03:10PM) https://ift.tt/3gCc0nL Academic2.ru is tracked by us since October, 2019. Over the time it has been ranked as high as 181 199 in the world, while most of its traffic comes from Russian Federation, where it reached as high as 19 317 position. Store.academic2.ru receives less than 1% of its total traffic. It was hosted by Hetzner Online GmbH. Store.academic2 has the lowest Google pagerank and bad results in terms of Yandex topical citation index. We found that Store.academic2.ru is poorly 'socialized' in respect to any social network. According to Google safe browsing analytics, Store.academic2.ru is quite a safe domain with no visitor reviews. Adblock test (Why?) via full digest https://ift.tt/3gCc0nL ============================ Image - (added at November 21, 2021 at 04:10PM) https://ift.tt/3oH2bKg Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3oH2bKg ============================ Image - (added at November 21, 2021 at 04:10PM) https://ift.tt/3FCU74e Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3FCU74e ============================ Image - (added at November 21, 2021 at 05:10PM) https://ift.tt/3rcaxfZ Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3rcaxfZ ============================ Image - (added at November 21, 2021 at 07:10PM) https://ift.tt/3DxBa25 Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3DxBa25 ============================ https://ift.tt/3CGQhVv - (added at November 21, 2021 at 07:10PM) https://ift.tt/2ZbqcAu Vision Bot in Enacademic Enacademic via full digest https://t.me/enacademicgroup/6675927?embed=1 ============================ Image - (added at November 21, 2021 at 08:10PM) https://ift.tt/3oH2bKg Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3oH2bKg ============================ academic2 - (added at November 21, 2021 at 08:10PM) https://ift.tt/30E4GEO Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/30E4GEO ============================ https://ift.tt/3nzkUba - (added at November 21, 2021 at 08:10PM) https://ift.tt/3Fqb5CG Enacademic via full digest https://ift.tt/3Fqb5CG ============================ Image - (added at November 21, 2021 at 10:10PM) https://ift.tt/3FCU74e Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3FCU74e ============================ Image - (added at November 21, 2021 at 11:10PM) https://ift.tt/3rcaxfZ Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3rcaxfZ ============================ https://ift.tt/2Z85EZt - (added at November 22, 2021 at 12:10AM) https://ift.tt/3cwVTam English: via full digest https://ift.tt/3nvjsqo ============================ https://ift.tt/3x2Csj1 - (added at November 20, 2021 at 08:10AM) https://ift.tt/3FprOWC Russian: Wedbush Chooses Apple as FAANG 2002 Favorite Stock years together (RSS) Cloud technology spending is expected to reach $1 trillion over the next decade as work-related remote communication grows together (RSS) Adblock test (Why?) via full digest https://ift.tt/3FprOWC ============================ academic2 - (added at November 20, 2021 at 09:10AM) https://ift.tt/30QsmpM Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/30QsmpM ============================ UCASU Confirmed $0 - (added at November 20, 2021 at 09:10AM) https://ift.tt/3qV6dBh Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qV6dBh ============================ academic2 - (added at November 20, 2021 at 09:10AM) https://ift.tt/3qSgiyW Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qSgiyW ============================ academic2.ru ² | Telegram Webview: academic2ru/361144 - (added at November 20, 2021 at 09:10AM) https://ift.tt/3zQRf1a tg-me.com/academic2ru/361144 Create: 2021-08-31 Last Update: 2021-11-16 23:42:58 academic2.ru full Academic2.Ru - Academic2 | WebSite Info http://store.academic2.ru.apescout.com/img/as_logo_fbg_share.png Traffic estimate for Academic2.ru is about 1,980 unique visits and 2,376 page views per day. Each unique visitor makes about 1.2 page views on average. According to traffic estimate, Academic2.ru should earn about $15.11 per day from the advertising revenue, which implies that this website is worth about $6,045.80. Alexa Traffic Rank estimates that it is ranked number 334,895 in the world and 0.0022% of global Internet users are visiting Academic2.ru on a regular basis. Website hosting location for Academic2.ru is: N/A. Server IP address: 138.201.81.43 Earnings ReportStore.academic2.ru Estimated Value $6,045.80 Store.academic2.ru Estimated Daily Revenue $15.11 Store.academic2.ru Estimated Monthly Revenue $453.43 Estimated Yearly Revenue of Store.academic2.ru $5,516.79 Traffic ReportDaily Unique Visitors at Store.academic2.ru 1,980 Monthly Unique Visitors at Store.academic2.ru 59,400 Daily Pageviews at Store.academic2.ru 2,376 (1.2 per day) Montly Pageviews at Store.academic2.ru 71,280 Daily PageViews Per User at Store.academic2.ru 1.2 Alexa Global Rank at Store.academic2.ru 334,895 Alexa Reach at Store.academic2.ru 0.0022% of global Internet users Alexa Backlinks at Store.academic2.ru 64 Average Page Load Time at Store.academic2.ru 0 Country ReportCountry Alexa Rank PageViews Visitors Russian Federation 33633 58.1% 62.2% Kazakhstan 6871 23.9% 22.7% OTHER 18.0% 15.1% Contributing Subdomains at Academic2.ruDomain Reach PageViews Per User translate.academic2.ru 51.25% 55.30% 1 academic2.ru 15.96% 13.92% 1 OTHER 0 30.91% 0 Social Report of Academic2.ruFacebook Shares 0 Facebook Comnents 0 Google Plus Shares 0 Vkontakte Shares 0 Pinterest Shares 0 LinkedIn Shares 0 StumbleUpon Shares 0 Xing Shares 0 Xing Comments 0 Xing Clicks 0 Xing Reach 0 Hosting InfoServer IP N/A ASN N/A ISP N/A Server Location N/A Google Safe BrowsingStore.academic2.ru is not currently listed as suspicious Http Header of Academic2.ruCurrently Not Available DNS Lookup of Academic2.ruType Ip Target TTL A 3.234.104.255 59 A 50.16.49.81 59 A 18.232.245.187 59 A 52.86.133.10 59 A 35.175.60.16 59 NS flamingo.ezoicns.com 172799 NS lionfish.ezoicns.com 172799 NS starfish.ezoicns.com 172799 NS tortoise.ezoicns.com 172799 SOA 900 MX mx.yandex.net 43200 TXT 900 TXT 900 TXT 900 TXT 900 WhoIs Lookup of Academic2.ruStore.academic2.ru Registration Date 2019-08-09 Store.academic2.ru Age: 2 years WhoIs: Adblock test (Why?) via full digest https://ift.tt/3cwVTam ============================ academic2 - (added at November 22, 2021 at 01:10AM) https://ift.tt/3nDZSYU Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3nDZSYU ============================ https://ift.tt/3nzkUba - (added at November 22, 2021 at 01:10AM) https://ift.tt/3Fqb5CG Enacademic via full digest https://ift.tt/3Fqb5CG ============================ academic2 - (added at November 22, 2021 at 01:10AM) https://ift.tt/30E4GEO Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/30E4GEO ============================ Enacademic feedspot (RSS) - (added at November 22, 2021 at 03:10AM) https://ift.tt/3FFUL0N Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3FFUL0N ============================ Image - (added at November 22, 2021 at 03:10AM) https://ift.tt/3kTQC1m Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3kTQC1m ============================ Image - (added at November 22, 2021 at 04:10AM) https://ift.tt/3oH2bKg Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3oH2bKg ============================ store.academic2.ru - Worth and traffic estimation | @academic2.ru... - (added at November 22, 2021 at 04:10AM) https://ift.tt/3lxZE2v Telegram Q&A Q: How does hottg.com work? Once you've set up a username, you can give people a hottg.com/username link. Opening that link on their phone will automatically fire up their Telegram app and open a chat with you. You can share username links with friends, write them on business cards or put them up on your website.This way people can contact you on Telegram without knowing your phone number. With Telegram, you can send messages, photos, videos and files of any type (doc, zip, mp3, etc), as well as create groups for up to 200,000 people or channels for b | ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Начальника полиции Долгопрудного задержали за переправку в США граждан Индии Posted: 24 Nov 2021 05:01 AM PST | ||
| Posted: 24 Nov 2021 05:40 AM PST Enacademic https://ift.tt/3xl8LK9 | ||
| Арктика пошла на рекорд холода. Вулканическая зима все ближе Posted: 24 Nov 2021 04:31 AM PST | ||
| Posted: 24 Nov 2021 05:40 AM PST Причаль https://ift.tt/3CNGOMc | ||
| Posted: 23 Nov 2021 11:14 PM PST academic2.ru full academic2.ru ² (@academic2ru) - Пост #215638 https://static10.tgstat.ru/channels/_0/f4/f49a9d16898d4ff55317a392ae6f33e7.jpg academic2.ru | ||
| Posted: 24 Nov 2021 06:24 AM PST | ||
| Posted: 24 Nov 2021 03:51 AM PST  | ||
| Posted: 24 Nov 2021 05:40 AM PST Что у них в голове https://ift.tt/3DRQMO1 | ||
| 5 Black Friday Shopping Tips for New Homeowners Posted: 24 Nov 2021 06:00 AM PST  In order to score the best bargains, use these tips to ensure you're shopping strategically. READ MORE... | ||
| Comment your favourite anime please I have nothing to watch Posted: 24 Nov 2021 02:10 AM PST
| ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Видео для товаров полиция - Форма одежды Posted: 24 Nov 2021 05:03 AM PST | ||
| DBV Technologies To Participate In An Upcoming Investor Conference Posted: 24 Nov 2021 05:01 AM PST | ||
| IIROC Trading Resumption - MCLD Posted: 24 Nov 2021 06:14 AM PST VANCOUVER, BC, Nov. 24, 2021 /CNW/ - Trading resumes in: Company: mCloud Technologies Corp. TSX-Venture Symbol: MCLD All Issues: Yes Resumption (ET): 9:45 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions | ||
| These Are the Unexpected Christmas Decor Trends in 2021, According to Experts Posted: 24 Nov 2021 05:45 AM PST  From elfcore to pastels. READ MORE... | ||
| Posted: 24 Nov 2021 04:31 AM PST | ||
| OnePlus Plans To Announce A Foldable Smartphone, But Not Anytime Soon Posted: 24 Nov 2021 06:09 AM PST  OnePlus has managed to become quite a popular smartphone OEM over the years. Quite a few people would be interested to see a foldable smartphone from OnePlus, but it doesn't seem like that will happen anytime soon, even though the company has plans for it. OnePlus plans to announce a foldable smartphone, but don't expect it to arrive soonThis information comes from Yogesh Brar, a tipster. He claims that OnePlus is discussing a foldable internally, but that it won't happen for at least 12-15 months. So, don't hold your breath for a foldable in H1 2022, and it likely won't arrive in 2022 in general. Maybe in 2023. Why is that? Well, as some of you know, OnePlus, OPPO, and Vivo are all owned by a company called BBK Electronics. Based on the information provided by the source, BBK Electronics is focusing on OPPO's foldable efforts. OPPO is expected to announce its very first foldable smartphone next month, in December. This information surfaced several times thus far, and the tipster just repeated it, basically. As for OnePlus, the tipster claims that the company will expand to a new product category soon, tablets. In addition to that, the company is also considering some new wearables. OPPO already showed us what it can do when it comes to rollable phonesHe did not share any details regarding the products that are coming, but it will be interesting to see, that's for sure. OPPO did a really nice job with the OPPO X 2021 concept rollable. That is actually a functioning device, but it's not for sale. It will be interesting to see what can the company offer in the foldable space. Samsung did a great job with the Galaxy Z Fold 3 and Z Flip 3, so it will be difficult to compete with. OPPO released some great products in the past, so it will be interesting to see its take on foldables. OPPO's first foldable will likely launch in China first. We still don't have a confirmation or anything of the sort, though. If it is coming next month, though, OPPO will surely start teasing it soon. The post OnePlus Plans To Announce A Foldable Smartphone, But Not Anytime Soon appeared first on Android Headlines. | ||
| Mozilla прекращает поддержку менеджера паролей Firefox Lockwise Posted: 24 Nov 2021 05:01 AM PST | ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Mastercard Expands Support Of Latin America Real-Time Payments With Acquisition Of Arcus Posted: 24 Nov 2021 06:15 AM PST Mastercard (MA) - Get Mastercard Inc. (MA) Report today announced it has acquired Arcus FI, an alum of the company's Start Path program, to help support the delivery of bill pay solutions and other real-time payment applications across Latin America. With offices in New York and Mexico City, Arcus helps to enable bill pay and cash-in, cash-out services for some of the biggest billers, retailers, fintechs and traditional financial institutions in the U.S. and Mexico, with expansion into Latin America. Its flagship solution, the Arcus Pay Network, has access to the largest retailers and direct connection with many of the largest billers in Mexico. "The past year has shown how critical digital solutions are for people and businesses across the region," said Laura Cruz, division president for Mexico and Central America at Mastercard. "With the addition of the Arcus team, we will enhance existing payment experiences and create new opportunities to address every day needs by connecting more people to the digital economy." Arcus' platform recently received approval to enable payment processing, settlement and reconciliation via Mexico's real-time Interbank Electronic Payment System (Sistema de Pagos Electrónicos Interbancarios or SPEI). "Edrizio de la Cruz and I began this company to help immigrants like us have a proper way to track our finances and send money home. For nearly a decade, we have grown from those aspirations to help pave the way toward greater financial inclusion in Latin America," said Iñigo Rumayor, co-founder at Arcus. "We've tapped into some of the region's brightest minds, and built a world-class team alongside Marc Sacal, who has helped us expand beyond those initial cross-border payments to give people a greater control of their financial lives. Now, becoming part of the Mastercard family and a direct participant in the SPEI network expands what we can deliver to our customers." Arcus has helped to pioneer the adoption of digital payment solutions in Latin America. Today, the company supports fast and easy access to deposits, withdrawals and payment services. Expansion of Mastercard Bill Pay Arcus' technology, network and customer relationships will help accelerate the introduction of Mastercard Bill Pay to Latin America. Its existing customers issue the majority of household bills in Mexico and provide connection to a wide range of payment options via banks, fintechs and digital wallet providers. This same connectivity will deliver the channel for a broader suite of financial services. Mastercard Bill Pay allows consumers to view, manage and pay their household and other personal bills from within their preferred financial service provider's app — securely, conveniently and with full control. It is already live with banks and credit unions and a network of 135,000 billers in the US as Mastercard Bill Pay Exchange. For billers, Mastercard Bill Pay can eliminate the cost of mailing paper bills and processing cash and checks, offers better visibility of payment status, and helps them reconcile payments to customer accounts. Financial institutions benefit from increased relevance in their customers' daily lives, resulting in increased engagement and additional services and increased customer engagement. Arcus Customer Testimonials "Arcus is the ideal partner for us due to its real-time payment technology, which allows us to offer the fastest possible payment solutions for our clients," said Jorge Hernández Santoyo, corporate treasurer at Sky Mexico & Central America. "Arcus was the ideal technology partner for us due to their agile technology, real-time processing and strong Latin American presence," said Guillermo Vicando, CEO and co-founder of Bnext. "Arcus is the ideal partner for us due to its real-time payment technology, which allows us to offer the fastest possible payment solutions for our clients," said Karen Iglesias, electronic services and home delivery manager at 7-Eleven Mexico. "Arcus is the ideal partner for our needs. We can use its suite of solutions to provide our customers with an unmatched payment experience around utilities payment and cash options to pay their credit cards," said Martin Mexia, head of payments at RappiPay. "By partnering with Arcus, Cuenca saves its customers' time with a personalized, fair, and 100% friendly-digital finance experience which allows them to top-up phone plans and pay different bills." Bibiana Monterde, co-founder of Cuenca. About Mastercard Incorporated (MA) - Get Mastercard Inc. (MA) Report, www.mastercard.com Mastercard is a global technology company in the payments industry. Our mission is to connect and power an inclusive, digital economy that benefits everyone, everywhere by making transactions safe, simple, smart and accessible. Using secure data and networks, partnerships and passion, our innovations and solutions help individuals, financial institutions, governments and businesses realize their greatest potential. Our decency quotient, or DQ, drives our culture and everything we do inside and outside of our company. With connections across more than 210 countries and territories, we are building a sustainable world that unlocks priceless possibilities for all. About Arcus Arcus is a platform that enables any business to launch and offer innovative payment solutions across LatAm. Arcus' mission is to make payments possible for everyone. The world's largest and most innovative companies choose Arcus to accept and process payments across the Americas including BBVA, Santander, Walmart, 7-Eleven, and Rappi. Arcus was launched in 2013 through Y-Combinator. Arcus is currently growing its team, with 100+ employees, 100+ clients, and operations in 7 countries in Latin America. For more information, visit Arcusfi.com. Forward-Looking Statements This press release contains forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements. When used in this press release, the words "believe," "expect," "could," "may," "would," "will," "trend" and similar words are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements that relate to Mastercard's future prospects, developments and business strategies, as well as Mastercard's acquisition and operation of Ekata. We caution you to not place undue reliance on these forward-looking statements, as they speak only as of the date they are made. Except for the company's ongoing obligations under the U.S. federal securities laws, the company does not intend to update or otherwise revise the forward-looking information to reflect actual results of operations, changes in financial condition, changes in estimates, expectations or assumptions, changes in general economic or industry conditions or other circumstances arising and/or existing since the preparation of this press release or to reflect the occurrence of any unanticipated events. Many factors and uncertainties relating to the proposed transaction, our operations and our business environment, all of which are difficult to predict and many of which are outside of our control, influence whether any forward-looking statements can or will be achieved. Any one of these factors could cause our actual results or the impact of the acquisition to differ materially from those expressed or implied in writing in any forward-looking statements made by Mastercard or on its behalf. Such factors related to the completion and impact of the acquisition include, but are not limited to, whether all necessary conditions will be met, and whether the transaction will close on agreed terms and in a timely manner. For additional information on other factors related to Mastercard's overall business that could cause Mastercard's actual results to differ materially from expected results, please see the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent reports on Forms 10-Q and 8-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005986/en/ | ||
| Аллергия на холод: что это такое и как с ней бороться Posted: 24 Nov 2021 05:00 AM PST | ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Daily Digest: If New feed item from https://clck.ru/P5rK2, then Add to daily digest sent to analogin Posted: 23 Nov 2021 08:17 PM PST ----- [36 items] ----- ============================ Don't have Telegram yet? - (added at November 14, 2021 at 07:36AM) https://ift.tt/3qMAwKL Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3qMAwKL ============================ Image - (added at November 14, 2021 at 08:35AM) https://ift.tt/3FaSrOR Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3FaSrOR ============================ academic2 - (added at November 14, 2021 at 08:35AM) https://ift.tt/3kzU6FM Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3kzU6FM ============================ Don't have Telegram yet? - (added at November 14, 2021 at 10:35AM) https://ift.tt/3FhbBCH Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3FhbBCH ============================ academic2 - (added at November 14, 2021 at 11:35AM) https://ift.tt/3c9eSYA Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3c9eSYA ============================ academic2 academic2 - (added at November 14, 2021 at 12:35PM) https://ift.tt/3CeI9va Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3CeI9va ============================ https://ift.tt/3c6lxCu - (added at November 14, 2021 at 12:35PM) https://ift.tt/30j76bA العربية: تقرير سوق بطاقات الهدايا وبطاقات الحوافز في بولندا 2021-2025 يضم Jeronimo Martins SGPS و Schwarz Beteiligungs و Tesco و Auchan Group و Eurocash و Dirk Rossmann و Metro و Carrefour و Euro-net و IKEA معا (RSS) DUBLIN, Nov. 12 ، 2021 / PRNewswire / -- تمت إضافة تقرير "بطاقة الهدايا وبطاقة الحوافز في بولندا وديناميات النمو المستقبلية ( Databook) - حجم السوق والتوقعات (2016-2025) - تحديث Q2 2021" إلى ResearchAndMarkets.com عرض. وفقا لمسح Q2 2021 Global Gift Card ، من المتوقع أن تنمو صناعة بطاقات الهدايا في البلاد بنسبة 11.7 ٪ على أساس سنوي لتصل إلى 1478.1 مليون دولار أمريكي في عام 2021. تاريخيا ، سجل سوق بطاقات الهدايا في بولندا نموا مطردا بمعدل نمو سنوي مركب بلغ 9.1٪ خلال 2016-2020. كان سوق بطاقات الهدايا في عام 2020 مدفوعا بمجموعة واسعة من العوامل ، والتي دعمت النمو عبر قطاعات البيع بالتجزئة والشركات. وشملت العوامل الرئيسية نمو التجارة الإلكترونية ، وزيادة التبني لتحفيز الموظفين الذين يعملون عن بعد ، والإهداء الرقمي ، والمبادرات التي تقوم بها الحكومة ، والضيافة ، وصناعات السفر لإحياء النمو. على الرغم من تأثر سوق بطاقات الهدايا بسبب COVID-19 ، فمن المتوقع أن يرتد السوق مرة أخرى في الأرباع القادمة ، خاصة في H1 2021. حققت صناعة بطاقات الهدايا في بولندا أداء جيدا لتحمل تأثير التباطؤ الاقتصادي إلى جانب المشاعر السلبية للأعمال والمستهلكين بسبب الاضطراب الناجم عن تفشي Covid-19. على الرغم من التحديات على المدى القريب في عام 2021 ، لا تزال قصة النمو المتوسطة والطويلة الأجل لبطاقات الهدايا في بولندا قوية. من المتوقع أن تنمو صناعة بطاقات الهدايا في بولندا بشكل مطرد في H1 2021 وتسجل نموا قويا في H2 2021. من المتوقع أن يستمر زخم النمو في النمو خلال فترة التوقعات ، حيث سجل معدل نمو سنوي مركب بنسبة 9.2٪ خلال 2021-2025. سيرتفع سوق بطاقات الهدايا في البلاد من 1322.9 مليون دولار أمريكي في عام 2020 ليصل إلى 2099.0 مليون دولار أمريكي بحلول عام 2025. يقدم هذا التقرير تحليلا مفصلا يركز على البيانات لبطاقات الهدايا وسوق بطاقات الحوافز للشركات إلى جانب سلوك المستهلك وديناميكيات إنفاق التجزئة في بولندا. مع أكثر من 200 مؤشرات الأداء الرئيسية على المستوى القطري ، يوفر هذا التقرير فهما شاملا لديناميات سوق الهدايا وبطاقات الحوافز. النطاق حلقة مغلقة حصة السوق بطاقة هدية من قبل تجار التجزئة الرئيسية Jeronimo Martins SGPS SA Schwarz Beteiligungs GmbH Tesco Plc Auchan Group SA Eurocash SA ديرك روسمان كجم Metro AG كارفور Euro-net sp zoo Inter Ikea Systems BV إجمالي الإنفاق على الهدايا في بولندا حسب قطاع المستهلك (التجزئة والشركات) حسب فئات المنتجات (13 شريحة) حسب قطاعات التجزئة (7 قطاعات) حجم سوق بطاقات الهدايا من قبل مؤشرات الأداء الرئيسية عبر قطاعات المستهلكين في بولندا إجمالي قيمة الحمل قيمة الصفقة القيمة غير المستخدمة متوسط القيمة لكل معاملة حجم المعاملات متوسط قيمة البطاقة المشتراة عدد البطاقات حجم سوق بطاقات الهدايا حسب شريحة المستهلكين في بولندا... عرض المشاركة الأصلية Adblock test (Why?) via full digest https://ift.tt/30j76bA ============================ Don't have Telegram yet? - (added at November 14, 2021 at 02:35PM) https://ift.tt/3HixwLH Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3HixwLH ============================ academic2 - (added at November 14, 2021 at 03:35PM) https://ift.tt/3c7IvcH Don't have Telegram yet? Try it now! Context Embed View In Channel Copy Adblock test (Why?) via full digest https://ift.tt/3c7IvcH ============================ Academic2.Ru - Academic2 | WebSite Info - (added at November 14, 2021 at 04:35PM) https://ift.tt/3g1ESIk Traffic estimate for Academic2.ru is about 1,980 unique visits and 2,376 page views per day. Each unique visitor makes about 1.2 page views on average. According to traffic estimate, Academic2.ru should earn about $15.11 per day from the advertising revenue, which implies that this website is worth about $6,045.80. Alexa Traffic Rank estimates that it is ranked number 334,895 in the world and 0.0022% of global Internet users are visiting Academic2.ru on a regular basis. Website hosting location for Academic2.ru is: N/A. Server IP address: 138.201.81.43 Earnings Report Estimated Value of Store.academic2.ru $6,045.80 Store.academic2.ru Estimated Daily Revenue $15.11 Estimated Monthly Revenue of Store.academic2.ru $453.43 Store.academic2.ru Estimated Yearly Revenue $5,516.79 Traffic Report Daily Unique Visitors at Store.academic2.ru 1,980 Monthly Unique Visitors at Store.academic2.ru 59,400 Daily Pageviews at Store.academic2.ru 2,376 (1.2 per day) Montly Pageviews at Store.academic2.ru 71,280 Daily PageViews Per User at Store.academic2.ru 1.2 Alexa Global Rank at Store.academic2.ru 334,895 Alexa Reach at Store.academic2.ru 0.0022% of global Internet users Alexa Backlinks at Store.academic2.ru 64 Average Page Load Time at Store.academic2.ru 0 Country Report Country Alexa Rank PageViews Visitors Russian Federation 33633 58.1% 62.2% Kazakhstan 6871 23.9% 22.7% OTHER 18.0% 15.1% Contributing Subdomains at Academic2.ru Domain Reach PageViews Per User translate.academic2.ru 51.25% 55.30% 1 academic2.ru 15.96% 13.92% 1 OTHER 0 30.91% 0 Social Report of Academic2.ru Facebook Shares 0 Facebook Comnents 0 Google Plus Shares 0 Vkontakte Shares 0 Pinterest Shares 0 LinkedIn Shares 0 StumbleUpon Shares 0 Xing Shares 0 Xing Comments 0 Xing Clicks 0 Xing Reach 0 Hosting Info Server IP N/A ASN N/A ISP N/A Server Location N/A Google Safe Browsing Store.academic2.ru is not currently listed as suspicious Http Header of Academic2.ru Currently Not Available DNS Lookup of Academic2.ru Type Ip Target TTL A 3.234.104.255 59 A 50.16.49.81 59 A 18.232.245.187 59 A 52.86.133.10 59 A 35.175.60.16 59 NS flamingo.ezoicns.com 172799 NS lionfish.ezoicns.com 172799 NS starfish.ezoicns.com 172799 NS tortoise.ezoicns.com 172799 SOA 900 MX mx.yandex.net 43200 TXT 900 TXT 900 TXT 900 TXT 900 WhoIs Lookup of Academic2.ru Store.academic2.ru Registration Date 2019-08-09 Store.academic2.ru Age: 2 years WhoIs: WhoIs lookup results from whois.tcinet.ru server: domain: ACADEMIC2.RU nserver: flamingo.ezoicns.com. nserver: lionfish.ezoicns.com. nserver: starfish.ezoicns.com. state: REGISTERED, DELEGATED, VERIFIED person: Private Person registrar: RU-CENTER-RU admin-contact: https://www.nic.ru/whois created: 2019-08-09T01:22:10Z paid-till: 2021-08-09T01:22:10Z free-date: 2021-09-09 source: TCI Last updated on 2021-03-10T10 This entry was originally posted at https://analogindex.dreamwidth.org/3285128.html. Please comment | ||
| Путин, что ты делаешь, прекрати Posted: 24 Nov 2021 06:29 AM PST https://www.tagesschau.de/inland/bverfg-erschliessungskosten-101.html  Жителей Германии заставляют платить за строительство дорог и тротуаров! Написал clayman на mp.d3.ru / комментировать | ||
| Posted: 24 Nov 2021 05:01 AM PST | ||
| Posted: 24 Nov 2021 05:40 AM PST Don't have Telegram yet? https://ift.tt/3r6Ojvy | ||
| This TikTok-Famous Planner Has Helped Make My Busy Days Way More Manageable — and It’s on Sale! Posted: 24 Nov 2021 05:45 AM PST  The secret: Less is more. READ MORE... | ||
| PAOG Acquisition To Expand CBD IP Portfolio Scheduled To Close December 3rd Posted: 24 Nov 2021 06:15 AM PST Sandusky, OH, Nov. 24, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the acquisition of an exclusive license to patented cannabis extraction process that will expand the company's existing CBD intellectual property is scheduled to close next week, on Friday, December 3 rd. Last year, the company acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). Now, the company will acquire an exclusive license to the patent itself from Puration, Inc. (OTC Pink: PURA) PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property. The acquisition is expected to close in early December. Learn more about PAOG at www.paogroupinc.com . Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release. CONTACT INFORMATIONContact Us: Jim DiPrima 888-272-6472 info@pao.group | ||
| Don't have Telegram yet? Try it now! Posted: 24 Nov 2021 05:01 AM PST |
| You are subscribed to email updates from together. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
![[link]](https://i.redd.it/j8ydfjh1qi181.jpg){kind=link}
Комментариев нет:
Отправить комментарий